COVAXIN
COVID-19 Vaccine Update: Bharat Biotech's Partner Ocugen Seeks Approval for Covaxin in Canada
WHO Likely To Decide on COVID-19 Vaccine COVAXIN’s Inclusion in Emergency Use List in 4–6 Weeks
Covaxin COVID-19 Vaccine Shows 77.8% Overall Efficacy, 65.2% Protection Against Delta Variant, Claims Bharat Biotech in Results From Phase 3 Clinical Trials
India in Touch With EU Members for Reciprocal Acceptance of COVID-19 Vaccines, Says Ministry of External Affairs
COVID-19 Vaccine Update: SII's Covishield Cleared by Switzerland, Iceland, 7 EU Nations for Travel, Day After India's Request
India Offers Reciprocal Exemption of EU Digital COVID Certificate on Inclusion of Covishield, Covaxin Vaccine
COVID-19 Vaccine Shortage in Punjab: CM Amarinder Singh Urges Centre To Supply More Doses of Vaccine to the State
Delhi Govt Requests Centre To Replenish COVID-19 Vaccine Stock To Continue High Rate of Vaccination
COVID-19 Vaccine Update: 51.6 Crore Vaccine Doses Would Be Made Available by July 31, Over 35 Crore Already Provided, Centre Tells Supreme Court
From Pfizer to Covaxin, Here's a Comparison and Efficacy Rates of All COVID-19 Vaccines
Mamata Banerjee Writes to PM Narendra Modi To Get COVID-19 Vaccine Covaxin Authenticated by WHO
India Likely To Have COVID-19 Vaccine for Children Above 2 Years by September-October: AIIMS Director Dr Randeep Guleria
Covaxin Phase 3 Trial Data: DCGI’s Expert Panel Says Bharat Biotech’s Vaccine 77.8% Effective
Google Trends